Hammer M - Search Results

1

A comparison of preferences for two GLP-1 products--liraglutide and exenatide--for the treatment of type 2 diabetes.

Polster M, Zanutto E, McDonald S, Conner C, Hammer M. Polster M, et al. Among authors: hammer m. J Med Econ. 2010;13(4):655-61. doi: 10.3111/13696998.2010.529377. Epub 2010 Nov 1. J Med Econ. 2010. PMID: 21034377 Free article.

2

Results of a model analysis of the cost-effectiveness of liraglutide versus exenatide added to metformin, glimepiride, or both for the treatment of type 2 diabetes in the United States.

Lee WC, Conner C, Hammer M. Lee WC, et al. Among authors: hammer m. Clin Ther. 2010 Sep;32(10):1756-67. doi: 10.1016/j.clinthera.2010.08.010. Clin Ther. 2010. PMID: 21194600

3

Predictors of glycemic control and diabetes-related costs among type 2 diabetes patients initiating therapy with liraglutide in the United States.

Durden E, Lenhart G, Lopez-Gonzalez L, Hammer M, Langer J. Durden E, et al. Among authors: hammer m. J Med Econ. 2016;19(4):403-13. doi: 10.3111/13696998.2015.1131703. Epub 2016 Jan 8. J Med Econ. 2016. PMID: 26653068 Free article.

4

Costs of managing severe hypoglycaemia in three European countries.

Hammer M, Lammert M, Mejías SM, Kern W, Frier BM. Hammer M, et al. J Med Econ. 2009;12(4):281-90. doi: 10.3111/13696990903336597. J Med Econ. 2009. PMID: 20001570 Free article.

5

Clinical effectiveness of liraglutide across body mass index in patients with type 2 diabetes in the United States: a retrospective cohort study.

Chitnis AS, Ganz ML, Benjamin N, Langer J, Hammer M. Chitnis AS, et al. Among authors: hammer m. Adv Ther. 2014 Sep;31(9):986-99. doi: 10.1007/s12325-014-0153-5. Epub 2014 Sep 23. Adv Ther. 2014. PMID: 25245811 Free PMC article.

6

Impact of medication adherence and persistence on clinical and economic outcomes in patients with type 2 diabetes treated with liraglutide: a retrospective cohort study.

Buysman EK, Liu F, Hammer M, Langer J. Buysman EK, et al. Among authors: hammer m. Adv Ther. 2015 Apr;32(4):341-55. doi: 10.1007/s12325-015-0199-z. Epub 2015 Apr 2. Adv Ther. 2015. PMID: 25832470 Free PMC article.

7

Real-world clinical and economic outcomes of liraglutide versus sitagliptin in patients with type 2 diabetes mellitus in the United States.

Li Q, Chitnis A, Hammer M, Langer J. Li Q, et al. Among authors: hammer m. Diabetes Ther. 2014 Dec;5(2):579-90. doi: 10.1007/s13300-014-0084-9. Epub 2014 Sep 26. Diabetes Ther. 2014. PMID: 25256818 Free PMC article.

8

Prevalence and healthcare costs of obesity-related comorbidities: evidence from an electronic medical records system in the United States.

Li Q, Blume SW, Huang JC, Hammer M, Ganz ML. Li Q, et al. Among authors: hammer m. J Med Econ. 2015;18(12):1020-8. doi: 10.3111/13696998.2015.1067623. Epub 2015 Sep 4. J Med Econ. 2015. PMID: 26134917 Free article.

9

Reporting error in weight and its implications for bias in economic models.

Cawley J, Maclean JC, Hammer M, Wintfeld N. Cawley J, et al. Among authors: hammer m. Econ Hum Biol. 2015 Dec;19:27-44. doi: 10.1016/j.ehb.2015.07.001. Epub 2015 Jul 23. Econ Hum Biol. 2015. PMID: 26256130

10

Variation in the risk of progression between glycemic stages across different levels of body mass index: evidence from a United States electronic health records system.

Blume SW, Li Q, Huang JC, Hammer M, Graf TR. Blume SW, et al. Among authors: hammer m. Curr Med Res Opin. 2015 Jan;31(1):115-24. doi: 10.1185/03007995.2014.971356. Epub 2014 Oct 16. Curr Med Res Opin. 2015. PMID: 25266974

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,358 results

Search Page

Filters